Cagent Vascular Reports First Human Use of Serranator® SONIC IVL System and Closes Oversubscribed $41M Series D Financing

Financing supports clinical advancement and commercialization of the company’s dual-modality IVL platform, with proceeds funding peripheral commercial launch and coronary program development WAYNE, Pa.–( BUSINESS WIRE )–Cagent Vascular, Inc., a leader in endovascular technologies, today announced two milestones: the successful completion of first human-use cases with the Serranator® SONIC Intravascular Lithotripsy (IVL) System and the closing of a $41 million Series D financing round. The Serranator® SONIC IVL System brings together Cagent Vascular’s Serranator® Serration Remodeling Therapy